VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with operational headquarters at the La Trobe University in Melbourne, Australia. VivaZome aims to develop and commercialise customised exosome-based therapies for debilitating and life-threatening disorders, with a focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies, intellectual property and manufacturing processes that apply generically to exosome therapies. These will underpin the Company’s development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech communities. VivaZome acknowledges the support of the Department of Industry and Science through the CRC-P program, and the contribution of its CRC-P partners: Australian National University, the University of Queensland, La Trobe University, Cytiva and SeerPharma Pty Ltd.
